Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 1
1992 3
1993 4
1994 2
1995 4
1996 2
1997 2
1998 3
1999 2
2001 3
2002 5
2003 3
2004 6
2005 3
2006 1
2007 2
2008 4
2009 4
2010 1
2011 3
2012 6
2013 1
2014 6
2015 4
2016 4
2017 4
2018 10
2019 6
2020 6
2021 9
2022 5
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Spatial mapping of mitochondrial networks and bioenergetics in lung cancer.
Han M, Bushong EA, Segawa M, Tiard A, Wong A, Brady MR, Momcilovic M, Wolf DM, Zhang R, Petcherski A, Madany M, Xu S, Lee JT, Poyurovsky MV, Olszewski K, Holloway T, Gomez A, John MS, Dubinett SM, Koehler CM, Shirihai OS, Stiles L, Lisberg A, Soatto S, Sadeghi S, Ellisman MH, Shackelford DB. Han M, et al. Among authors: wolf dm. Nature. 2023 Mar;615(7953):712-719. doi: 10.1038/s41586-023-05793-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922590 Free PMC article.
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network; Stuart JM, Benz CC, Laird PW. Hoadley KA, et al. Among authors: wolf dm. Cell. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022. Cell. 2018. PMID: 29625048 Free PMC article.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J; I-SPY2 Investigators; Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Wolf DM, et al. Cancer Cell. 2022 Jun 13;40(6):609-623.e6. doi: 10.1016/j.ccell.2022.05.005. Epub 2022 May 26. Cancer Cell. 2022. PMID: 35623341 Free PMC article. Clinical Trial.
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ. Magbanua MJM, et al. Among authors: wolf dm. Ann Oncol. 2021 Feb;32(2):229-239. doi: 10.1016/j.annonc.2020.11.007. Epub 2020 Nov 21. Ann Oncol. 2021. PMID: 33232761 Free PMC article.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Among authors: wolf dm. Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4. Cancer Cell. 2023. PMID: 37146605 Free article.
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Pusztai L, et al. Among authors: wolf dm. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. Cancer Cell. 2021. PMID: 34143979 Free article. Clinical Trial.
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. Ruiz-Saenz A, et al. Among authors: wolf dm. Nat Cancer. 2023 Feb;4(2):240-256. doi: 10.1038/s43018-022-00508-5. Epub 2023 Feb 9. Nat Cancer. 2023. PMID: 36759733 Free PMC article.
ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.
Wang S, Böhnert V, Joseph AJ, Sudaryo V, Skariah G, Swinderman JT, Yu FB, Subramanyam V, Wolf DM, Lyu X, Gilbert LA, Van't Veer LJ, Goodarzi H, Li L. Wang S, et al. Among authors: wolf dm. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2313693120. doi: 10.1073/pnas.2313693120. Epub 2023 Dec 20. Proc Natl Acad Sci U S A. 2023. PMID: 38117852 Free PMC article.
130 results